Literature DB >> 33613574

Parallels in Sepsis and COVID-19 Conditions: Implications for Managing Severe COVID-19.

Charles Ochieng' Olwal1,2, Nora Nghuchuzie Nganyewo1,2, Kesego Tapela1,2, Alexandra Lindsey Djomkam Zune1,2, Oloche Owoicho1,2, Yaw Bediako1, Samuel Duodu1,2.   

Abstract

Sepsis is a life-threatening systemic illness attributed to a dysregulated host response to infection. Sepsis is a global burden killing ~11 million persons annually. In December 2019, a novel pneumonia condition termed coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), emerged and has resulted in more than 1,535,982 deaths globally as of 8th December 2020. These two conditions share many pathophysiological and clinical features. Notably, both sepsis and COVID-19 patients experience consumptive thrombocytopenia, haemolytic anaemia, vascular microthrombosis, multi-organ dysfunction syndrome, coagulopathy, septic shock, respiratory failure, fever, leukopenia, hypotension, leukocytosis, high cytokine production and high predisposition to opportunistic infections. Considering the parallels in the immunopathogenesis and pathophysiological manifestations of sepsis and COVID-19, it is highly likely that sepsis care, which has a well-established history in most health systems, could inform on COVID-19 management. In view of this, the present perspective compares the immunopathogenesis and pathophysiology of COVID-19 and non-SARS-CoV-2 induced sepsis, and lessons from sepsis that can be applicable to COVID-19 management.
Copyright © 2021 Olwal, Nganyewo, Tapela, Djomkam Zune, Owoicho, Bediako and Duodu.

Entities:  

Keywords:  COVID-19; SARS-CoV-2; coronavirus; cytokine storm; hypovolemia; immunosuppression; sepsis

Year:  2021        PMID: 33613574      PMCID: PMC7886971          DOI: 10.3389/fimmu.2021.602848

Source DB:  PubMed          Journal:  Front Immunol        ISSN: 1664-3224            Impact factor:   7.561


  14 in total

1.  HDAC Inhibition as Potential Therapeutic Strategy to Restore the Deregulated Immune Response in Severe COVID-19.

Authors:  Chiara Ripamonti; Valeria Spadotto; Pietro Pozzi; Andrea Stevenazzi; Barbara Vergani; Mattia Marchini; Giovanni Sandrone; Emanuele Bonetti; Luca Mazzarella; Saverio Minucci; Christian Steinkühler; Gianluca Fossati
Journal:  Front Immunol       Date:  2022-05-03       Impact factor: 8.786

2.  Pancreatic Stone Protein as a Biomarker for Sepsis at the Emergency Department of a Large Tertiary Hospital.

Authors:  Titus A P de Hond; Jan Jelrik Oosterheert; Susan J M van Hemert-Glaubitz; Ruben E A Musson; Karin A H Kaasjager
Journal:  Pathogens       Date:  2022-05-09

3.  Monocyte distribution width as a novel sepsis indicator in COVID-19 patients.

Authors:  Laila Alsuwaidi; Saba Al Heialy; Nahid Shaikh; Firas Al Najjar; Rania Seliem; Aaron Han; Mahmood Hachim
Journal:  BMC Infect Dis       Date:  2022-01-04       Impact factor: 3.090

4.  Nitric Oxide: The Missing Factor in COVID-19 Severity?

Authors:  Alexandros Nikolaidis; Ron Kramer; Sergej Ostojic
Journal:  Med Sci (Basel)       Date:  2021-12-23

Review 5.  Cardiovascular Dysfunction in COVID-19: Association Between Endothelial Cell Injury and Lactate.

Authors:  Kun Yang; Matthew Holt; Min Fan; Victor Lam; Yong Yang; Tuanzhu Ha; David L Williams; Chuanfu Li; Xiaohui Wang
Journal:  Front Immunol       Date:  2022-03-23       Impact factor: 7.561

6.  Endogenous Carboxyhemoglobin Level Variation in COVID-19 and Bacterial Sepsis: A Novel Approach?

Authors:  Bianca-Liana Grigorescu; Irina Săplăcan; Ioana Roxana Bordea; Marius Petrisor; Oana Coman; Claudiu Ion Puiac; Ariana Toncean; Raluca Stefania Fodor
Journal:  Microorganisms       Date:  2022-01-27

7.  Prognostic value of copeptin and mid-regional proadrenomedullin in COVID-19-hospitalized patients.

Authors:  Rita Indirli; Alessandra Bandera; Luca Valenti; Ferruccio Ceriotti; Adriana Di Modugno; Mauro Tettamanti; Roberta Gualtierotti; Flora Peyvandi; Nicola Montano; Francesco Blasi; Giorgio Costantino; Veronica Resi; Emanuela Orsi; Maura Arosio; Giovanna Mantovani; Emanuele Ferrante
Journal:  Eur J Clin Invest       Date:  2022-02-07       Impact factor: 5.722

Review 8.  COVID-19 and Panax ginseng: Targeting platelet aggregation, thrombosis and the coagulation pathway.

Authors:  Yuan Yee Lee; Yixian Quah; Jung-Hae Shin; Hyuk-Woo Kwon; Dong-Ha Lee; Jee Eun Han; Jin-Kyu Park; Sung Dae Kim; Dongmi Kwak; Seung-Chun Park; Man Hee Rhee
Journal:  J Ginseng Res       Date:  2022-01-19       Impact factor: 5.735

9.  Preclinical Evaluation of Chicken Egg Yolk Antibody (IgY) Anti-RBD Spike SARS-CoV-2-A Candidate for Passive Immunization against COVID-19.

Authors:  Hendris Wongso; Isa Mahendra; Wyanda Arnafia; Idar Idar; Muhammad Yusuf; Arifudin Achmad; Holis A Holik; Ahmad Kurniawan; Iim Halimah; Maula E Sriyani; Teguh H A Wibawa; Muhamad B Febrian; Yanuar Setiadi; Eva M Widyasari; Isti Daruwati; Crhisterra E Kusumaningrum; Toto Subroto
Journal:  Vaccines (Basel)       Date:  2022-01-17

10.  Inflammation-Induced Coagulopathy Substantially Differs Between COVID-19 and Septic Shock: A Prospective Observational Study.

Authors:  Mélanie Dechamps; Julien De Poortere; Manon Martin; Laurent Gatto; Aurélie Daumerie; Caroline Bouzin; Marie Octave; Audrey Ginion; Valentine Robaux; Laurence Pirotton; Julie Bodart; Ludovic Gerard; Virginie Montiel; Alessandro Campion; Damien Gruson; Marie-Astrid Van Dievoet; Jonathan Douxfils; Hélène Haguet; Laure Morimont; Marc Derive; Lucie Jolly; Luc Bertrand; Laure Dumoutier; Diego Castanares-Zapatero; Pierre-François Laterre; Sandrine Horman; Christophe Beauloye
Journal:  Front Med (Lausanne)       Date:  2022-01-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.